Anbio Biotechnology (NNNN)
NASDAQ: NNNN · Real-Time Price · USD
13.55
-0.98 (-6.74%)
At close: Jun 29, 2026, 4:00 PM EDT
13.82
+0.27 (1.99%)
After-hours: Jun 29, 2026, 5:11 PM EDT
Company Description
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally.
The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Anbio Biotechnology
| Country | Germany |
| Founded | 2021 |
| IPO Date | Feb 19, 2025 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Michael Lau |
Contact Details
Address: Friedrich-Ebert-Anlage 35-37 Frankfurt am Main, 60327 Germany | |
| Phone | 49 698 7003 9170 |
| Website | anbiobiotechnology.com |
Stock Details
| Ticker Symbol | NNNN |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001982708 |
| CUSIP Number | G0367B105 |
| ISIN Number | KYG0367B1059 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Michael Lau M.B.A., Ph.D. | Chief Executive Officer |
| Suki Song CPA | Chief Financial Officer |
| Chris Tian | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 19, 2026 | 6-K | Report of foreign issuer |
| Apr 27, 2026 | 6-K | Report of foreign issuer |
| Apr 9, 2026 | 20-F/A | Filing |
| Apr 7, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Feb 17, 2026 | 6-K | Report of foreign issuer |
| Jan 26, 2026 | 6-K | Report of foreign issuer |
| Dec 30, 2025 | 6-K | Report of foreign issuer |
| Nov 13, 2025 | 6-K | Report of foreign issuer |
| Apr 28, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Feb 21, 2025 | 6-K | Report of foreign issuer |